CytoTronics has filed a notice of an exempt offering of securities to raise $13,500,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, CytoTronics is raising up to $13,500,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Jeffrey Abbott played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About CytoTronics
CytoTronics is commercializing technology emerging from the Harvard University labs to bring unique insights to drug discovery. A revolutionary approach to studying cell biology, powered by microchips. At CytoTronics, we are transforming cell biology discovery with our high-throughput, semiconductor-based platforms. Our Pixel systems provide live cell insights with single-cell resolution across all cell types. By seamlessly integrating semiconductors with conventional microplates, Pixel unlocks multi-modal electrical, electrochemical, and electrophysiological capabilities, delivering an unprecedented scope of data collection and scale-up for cell biology research, drug development, and pharmaceutical manufacturing.
To learn more about CytoTronics, visit http://www.cytotronics.com/
CytoTronics Linkedin Page: https://www.linkedin.com/company/cytotronics/
Contact:
Jeffrey Abbott, Chief Executive Officer
714-671-9704
https://www.linkedin.com/in/jeffrey-abbott/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.